MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Akero Therapeutics Cash and Cash Equivalents 2011-2026 | AKRO
Annual Cash and Cash Equivalents Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 340 M | 234 M | 250 M | 151 M | 187 M | 64.8 M | 76 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 340 M | 64.8 M | 186 M |
Quarterly Cash and Cash Equivalents Akero Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 176 M | 220 M | 340 M | 316 M | 310 M | 234 M | 270 M | 444 M | 258 M | 250 M | 374 M | - | 151 M | 150 M | 165 M | 158 M | 188 M | 187 M | 187 M | 187 M | 187 M | 64.8 M | 64.8 M | 64.8 M | 64.8 M | 76 M | 76 M | 9.81 M | - | 618 K | - | 618 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 444 M | 618 K | 178 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 1.06 | -1.85 % | $ 5.78 M |  China |
 |
Adagene
ADAG
|
75.2 M | $ 1.72 | 4.24 % | $ 96.8 M | China |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 203.22 | -2.65 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.5 | 5.11 % | $ 8.42 B |  Australia |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 64.63 | -0.57 % | $ 8.64 B |  USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.83 | -4.45 % | $ 467 M |  Britain |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Biogen
BIIB
|
2.38 B | $ 187.5 | 0.81 % | $ 27.3 B | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioVie
BIVI
|
17.5 M | $ 1.27 | -2.31 % | $ 1.88 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioXcel Therapeutics
BTAI
|
29.9 M | $ 1.97 | -1.5 % | $ 4.99 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 100.02 | 1.18 % | $ 27.2 B | Germany |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 27.76 | 0.05 % | $ 1.34 B | USA |
 |
CASI Pharmaceuticals
CASI
|
38.7 M | $ 1.12 | 4.71 % | $ 152 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.2 | -2.33 % | $ 9.14 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 10.82 | -1.37 % | $ 712 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
172 M | $ 11.15 | -1.85 % | $ 721 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Axon Enterprise
AXON
|
455 M | $ 631.42 | 3.01 % | $ 47.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.65 | -0.38 % | $ 16.6 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 94.84 | 0.88 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 9.4 | 1.46 % | $ 1.52 B | Britain |